**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Mounira Kharoubi, Hospital Henri Mondor, Referral  Center of Cardiac Amyloidosis, Créteil, France

**Main Body of the Abstract**
Cardiac amyloidosis (CA) has emerged as a rare disease responsible of heart complications with the development of specific therapies that can modify the natural history of the disease and outcomes. Data on prevailing practice patterns and long-term outcomes of CA are scarce.Nationally representative CA data from France are not available.The primary objective of HEAR is to describe the demographical, clinical, biological, and imaging characteristicsof patients with CA.The secondary objectives are to describe different types of amyloidosis and their evolution, the course of care and its evolution; to assess the quality of diagnostic tools; to describe the quality of life; the prognosis of the disease and its evolution;  the therapeutic management; to assess hospitalizations and therapeutic interventions.HEAR is also an excellent opportunity to share practices, evaluate and optimize the quality of healthcare of CA in France.HEAR REGISTRY is a French National, longitudinal, and multicentric registry, included three different groups of patients : Prospective, Retro-prospective and Retrospective, referred for suspicion of CA or with a confirmed diagnosis of CA.34 hospitals across France are participating since January 2021.6000 patients are expected be included.Demographics, clinical, laboratory, imaging, treatment, questionnaires quality of life were collected at baseline from all registered patients by using a structured questionnaire. We intend to obtain the in-hospital annual outcome data on mortality, cause of death, and repeated hospitalization events.HEAR REGISTRY will be the first French Nationally registry with a large representative of patient with CA aimed at providing crucial information on prevailing sub-etiology, distribution, and current practices in their management.



Healthcare Amyloidosis European Registry (HEAR REGISTRY): Study design and methods PA102 (#469)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.